×
About 755 results

ALLMedicine™ Prolactinoma Center

Research & Reviews  283 results

ITALIAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS (AME) AND INTERNATIONAL CHAPTER OF CLI...
https://doi.org/10.1530/EJE-21-0977
European Journal of Endocrinology; Cozzi R, Ambrosio MR et. al.

Jan 11th, 2022 - Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different clinical settings and always require an individually tailored approach. This is the reason why a panel of Italian neuroendocrine experts was charged with t...

ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
https://doi.org/10.1530/ERC-21-0215
Endocrine-related Cancer; Zhu J, Tang C et. al.

Nov 26th, 2021 - Dopamine agonist (DA) is the first choice for the treatment of prolactinomas, and drug resistance is unavoidable during treatment due to the heterogeneity of tumors. The two prolactinoma cell lines (GH3 cells and MMQ cells) were found to have diff...

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactino...
https://doi.org/10.1186/s12902-021-00900-9 10.1002/mgg3.1022 10.1007/s11102-005-5085-2 10.1007/s11102-019-00987-3 10.1007/s11102-009-0168-0 10.3389/fendo.2018.00768 10.1007/s11102-010-0237-4 10.1073/pnas.222319599 10.1159/000126764 10.3390/cancers11101618 10.1002/cncr.28864 10.1038/s41580-020-00322-w 10.1016/j.bbamcr.2007.03.010 10.1038/nrc2694 10.1016/j.ccr.2014.02.019 10.3390/ijms21176102 10.1016/j.tibs.2017.02.008 10.3748/wjg.v20.i29.9744 10.18632/oncotarget.7306 10.1038/srep13547 10.1111/jcmm.12718 10.1007/s10495-016-1223-8 10.3892/or.2017.5352 10.1074/jbc.M307591200 10.3389/fendo.2019.00330 10.1186/s12902-020-00619-z 10.1016/j.mce.2014.12.024 10.1016/S0303-7207(03)00236-3 10.1038/266640a0 10.1210/endo-107-4-1022 10.1210/endo-128-1-13 10.1159/000094308 10.1038/15275 10.1159/000014618 10.1177/019262339702500506 10.1055/s-0035-1546208 10.1016/j.pnpbp.2012.07.005 10.4158/EP-2018-0034 10.1677/erc.0.0080287 10.1007/s11102-013-0488-y 10.1210/jcem.85.9.6798 10.1530/EJE-14-0013 10.1159/000495775 10.2174/0929867320666131119155023 10.3390/ijms19082184 10.1111/jop.12707 10.1016/j.bbrc.2019.10.059 10.1016/j.phymed.2018.12.028 10.1186/1471-2407-8-375 10.3390/ijms21031102 10.1016/0014-5793(96)00255-4 10.1016/j.taap.2009.07.002 10.1074/jbc.273.12.6607 10.1172/JCI5257 10.1164/rccm.200207-664OC 10.1016/j.leukres.2006.11.006 10.1155/2020/3107290 10.1111/jcmm.13963 10.1016/j.bbrc.2019.09.070 10.1074/jbc.M202920200 10.1210/me.2013-1008 10.1159/000279753 10.1095/biolreprod62.6.1486
BMC Endocrine Disorders; Wang S, Wang A et. al.

Nov 25th, 2021 - Prolactinoma is a functional pituitary adenoma that secretes excessive prolactin. Dopamine agonists (DAs) such as bromocriptine (BRC) are the first-line treatment for prolactinomas, but the resistance rate is increasing year by year, creating a cl...

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic revie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590353
BMC Endocrine Disorders; Zou Y, Li D et. al.

Nov 15th, 2021 - Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal. However, few of them h...

Impact of Insurance and Income levels on Survival Rates in Prolactinomas.
https://doi.org/10.1016/j.ijrobp.2021.07.998
International Journal of Radiation Oncology, Biology, Phy... Madishetty S, Nam K et. al.

Oct 28th, 2021 - Prolactinoma is the most common type (∼40%) of functional pituitary adenoma. Patients with prolactinoma generally have a good prognosis with appropriate treatment. However, disparities in insurance and socioeconomic status can influence the outcom...

see more →

Guidelines  1 results

Pituitary incidentaloma: an endocrine society clinical practice guideline.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393422
The Journal of Clinical Endocrinology and Metabolism; Freda PU, Beckers AM et. al.

Apr 9th, 2011 - The aim was to formulate practice guidelines for endocrine evaluation and treatment of pituitary incidentalomas. Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails and one in-per...

see more →

Clinicaltrials.gov  5 results

Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
https://clinicaltrials.gov/ct2/show/NCT03973450

Sep 8th, 2021 - Recent epidemiological studies indicate that clinically relevant PiT have a prevalence around 1%. The Neuromed Scientific Institute for Research and Cure (IRCCS) is a third referral center for the diagnosis and treatment of patients with hypothala...

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
https://clinicaltrials.gov/ct2/show/NCT03457389

Mar 18th, 2020 - Prolactinoma patients will be assigned to a experimental group that maintains serum prolactin levels below 5 ng/mL and a control group that maintains normal serum prolactin levels. After that, cabergoline will be maintained at a therapeutic dose f...

Intraoperative Imaging of Pituitary Adenomas by OTL
https://clinicaltrials.gov/ct2/show/NCT02629549

Aug 6th, 2019 - Pituitary adenomas have an estimated prevalence in the population of approximately 10%, and although they are predominantly benign tumors, they can cause significant disability from mass effect (visual field deficits and cranial nerve deficits) an...

Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
https://clinicaltrials.gov/ct2/show/NCT03717454

Nov 20th, 2018 - The dopamine agonist(DA),such as cabergoline(CAB) and bromocriptine(BC), has been used widely in the treatment of prolactinomas, but its clinical use is hampered by intolerance and/or resistant in some patients. It had been showed that DA inhibit ...

The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism
https://clinicaltrials.gov/ct2/show/NCT00451672

Mar 23rd, 2007 - Primary aldosteronism (PA), a common curable disease of hypertension, is characterized by inappropriate production of aldosterone, which is at least partially autonomous of the renin-angiotensin system. A recent clinical study reported that patien...

see more →

News  8 results

Prolactin, the pituitary, and pregnancy: Where’s the balance?
https://www.mdedge.com/familymedicine/article/164370/pituitary-thyroid-adrenal-disorders/prolactin-pituitary-and-pregnancy/page/0/3
Clinical Endocrinology News;

Apr 26th, 2018 - What if the tumor grows in pregnancy? During pregnancy, high estrogen levels from the placenta can stimulate prolactinoma growth, and the dopamine agonist’s inhibitory effect is gone once that medication’s been stopped. This means that “We have bo.

The Case of the Famous Woman With a Bloated Belly
https://www.medscape.com/viewarticle/714607_4

Jan 11th, 2010 - How Would Mary Have Been Treated Today? Today, when a woman suspects pregnancy, she undergoes a rapid test for pregnancy. If the result is negative but symptoms, such as galactorrhea or amenorrhea, are still present, an occult prolactinoma might b...

Familial Pituitary Adenomas — Who Should be Tested for AIP Mutations?
https://www.medscape.com/viewarticle/769615

Abstract and Introduction Abstract Familial Isolated Pituitary Adenomas (FIPA), an autosomal dominant disease with low penetrance is being increasingly recognized. FIPA families can be divided into two distinct groups based on genetic and phenotyp...

Unmasked Testicular Seminoma During Use of Hormonal Transgender Woman Therapy
https://www.medscape.com/viewarticle/934344_1

Abstract and Introduction Abstract Management of gender-affirming hormone therapy (HT) in transgender women includes surveillance of testosterone (T) levels. Failure of T to suppress, despite adherence to therapy, warrants additional investigation...

Unmasked Testicular Seminoma During Use of Hormonal Transgender Woman Therapy
https://www.staging.medscape.com/viewarticle/934344

Abstract and Introduction Abstract Management of gender-affirming hormone therapy (HT) in transgender women includes surveillance of testosterone (T) levels. Failure of T to suppress, despite adherence to therapy, warrants additional investigation...

see more →

Patient Education  5 results see all →